Invesco Ltd. Neurocrine Biosciences Inc Transaction History

Invesco Ltd.

$503 Billion
Q1 2025

A detailed history of Invesco Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Invesco Ltd. holds 567,320 shares of NBIX stock, worth $68.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

567,320

Previous 949,512 40.25%

Holding current value

$68.2 Million

Previous $130 Million 51.59%

% of portfolio

0.01%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$107.22 - $153.29 $41 Million - $58.6 Million	-382,192 Reduced 40.25%	567,320 $62.7 Million
Q4 2024 Feb 13, 2025	BUY	$111.62 - $139.44 $8.35 Million - $10.4 Million	74,847 Added 8.56%	949,512 $130 Million
Q3 2024 Nov 12, 2024	SELL	$114.58 - $153.15 $43.9 Million - $58.7 Million	-383,439 Reduced 30.48%	874,665 $101 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $15.9 Million - $17.3 Million	121,162 Added 10.66%	1,258,104 $173 Million
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $60.4 Million - $66.6 Million	463,134 Added 68.73%	1,136,942 $157 Million
Q4 2023 Feb 12, 2024	BUY	$106.07 - $132.76 $30.5 Million - $38.2 Million	287,693 Added 74.51%	673,808 $88.8 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $16.6 Million - $20.6 Million	-176,245 Reduced 31.34%	386,115 $43.4 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $1.25 Million - $1.46 Million	-13,914 Reduced 2.41%	562,360 $53 Million
Q1 2023 May 12, 2023	SELL	$94.11 - $123.02 $80.1 Million - $105 Million	-851,005 Reduced 59.62%	576,274 $58.3 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $55.7 Million - $66.3 Million	521,568 Added 57.59%	1,427,279 $170 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $58.5 Million - $68.5 Million	635,394 Added 235.06%	905,711 $96.2 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1.4 Million - $1.85 Million	18,452 Added 7.33%	270,317 $26.4 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $2.12 Million - $2.77 Million	-29,253 Reduced 10.41%	251,865 $23.6 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $3.72 Million - $4.96 Million	-46,693 Reduced 14.24%	281,118 $23.9 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $66 Million - $75.9 Million	-766,088 Reduced 70.03%	327,811 $31.4 Million
Q2 2021 Aug 17, 2021	BUY	$89.43 - $102.27 $584,335 - $668,232	6,534 Added 0.6%	1,093,899 $106 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $369,895 - $504,345	4,224 Added 0.39%	1,087,365 $106 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $56.5 Million - $70.5 Million	-650,332 Reduced 37.52%	1,083,141 $104 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $21.1 Million - $29.7 Million	-219,836 Reduced 11.25%	1,733,473 $167 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $81.6 Million - $125 Million	959,127 Added 96.47%	1,953,309 $238 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $9.33 Million - $14.1 Million	-124,255 Reduced 11.11%	994,182 $86 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $17.8 Million - $24.3 Million	-204,879 Reduced 15.48%	1,118,437 $120 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $3.77 Million - $4.57 Million	45,004 Added 3.52%	1,323,316 $119 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $46.6 Million - $58.8 Million	-644,606 Reduced 33.52%	1,278,312 $108 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $14.3 Million - $18.9 Million	-205,944 Reduced 9.67%	1,922,918 $169 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $145 Million - $265 Million	2,128,862 New	2,128,862 $152 Million

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account